about
Premature B-cell senescence as a consequence of chronic immune activation.Diagnostic value of soluble triggering receptor expressed on myeloid cells in paediatric sepsis: a systematic reviewgp91phox-dependent expression of platelet CD40 ligandThe Pro78 residue regulates the capacity of the human immunodeficiency virus type 1 Nef protein to inhibit recycling of major histocompatibility complex class I molecules in an SH3-independent manner.Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.Trans fatty acids and atopic eczema/dermatitis syndrome: the relationship with a free radical cis-trans isomerization of membrane lipids.The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children.The European paediatric legislation: benefits and perspectives.Different degrees of NADPH oxidase 2 regulation and in vivo platelet activation: lesson from chronic granulomatous diseaseTherapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC)Immune deficiency caused by impaired expression of nuclear factor-kappaB essential modifier (NEMO) because of a mutation in the 5' untranslated region of the NEMO geneIntergenerational and intrafamilial phenotypic variability in 22q11.2 deletion syndrome subjects.Atopic dermatitis: molecular mechanisms, clinical aspects and new therapeutical approaches.Zinc-dependent chemotactic defect in an infant with acrodermatitis.Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis.Understanding probiotics' role in allergic children: the clue of gut microbiota profiling.Accuracy of serum procalcitonin for the diagnosis of sepsis in neonates and children with systemic inflammatory syndrome: a meta-analysis.CD4 and major histocompatibility complex class I downregulation by the human immunodeficiency virus type 1 nef protein in pediatric AIDS progression.Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children.Italian consensus statement on paediatric HIV infection.Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.Chronic granulomatous disease presenting with salmonella brain abscesses.Downfall of the current antibody correlates of influenza vaccine response in yearly vaccinated subjects: Toward qualitative rather than quantitative assays.Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects.Immunisation practices in centres caring for children with perinatally acquired HIV: A call for harmonisation.The case of an APDS patient: Defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment.Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity.Immunological and virological investigation in patients with lymphoadenopathy syndrome and in a population at risk for acquired immunodeficiency syndrome (AIDS), with particular focus on the detection of antibodies to human T-lymphotropic retrovirusLongitudinal Evaluation of Immune Reconstitution and B-cell Function After Hematopoietic Cell Transplantation for Primary Immunodeficiency.Neuroblastoma and insulin-like growth factor system. New insights and clinical perspectives.Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype.Diverse T-cell receptor CDR3 length patterns in human CD4+ and CD8+ T lymphocytes from newborns and adults.Defective B-cell proliferation and maintenance of long-term memory in patients with chronic granulomatous disease.Inflammatory Bowel Disease in Chronic Granulomatous Disease: an emerging problem over a twenty years' experience.In vitro susceptibility of different human T-cell subpopulations and resistance of large granular lymphocytes to HTLV-I infection.B-sides serologic markers of immunogenicity in kidney transplanted patients: report from 2012-2013 flu vaccination experience.Clinical features and follow-up in patients with 22q11.2 deletion syndrome.Early highly active antiretroviral therapy enhances B-cell longevity: a 5 year follow up.Antibody but not memory B-cell responses are tuned-down in vertically HIV-1 infected children and young individuals being vaccinated yearly against influenza.Etiology, clinical outcome, and laboratory features in children with neutropenia: analysis of 104 cases.
P50
Q27693281-7FE64287-F270-4AB3-B805-141E86AABFFEQ28076186-C1A034B6-9B16-45DB-BE0A-EE6697D3113DQ28208601-73FC0FDC-20B5-487E-9DDD-D25DDD23F4EEQ30159723-593FBDE7-6307-4254-94DA-6CB06ED8FECCQ30412019-1E3205D4-A0ED-4D7B-BC37-53F11931B3FFQ33224328-8CE6B879-5526-46E5-BC55-E263EC54E402Q33788780-3C845484-7D0C-457F-9678-47987F0CF6C0Q34105078-196AFBFF-9D9F-4670-81B8-B0F98255BD5DQ35021974-659B9E05-544A-48DF-A5A3-C2385E5AE699Q35060232-89157900-BCCB-4946-BD51-64D00F72785EQ35072760-4170156C-DC24-4A05-B50F-6B9EDB244D55Q35079561-8E0BD6BC-03CA-4D04-ABD8-6ADB4DE349D0Q35083236-4914E473-2D56-41CC-B43D-1878B0CC6E49Q35114999-0A236A12-45BA-4CED-88F4-FC338AA3A9F9Q35618854-CBF983CA-7E19-4DB4-8280-2877EC5B63A9Q35741517-E34595F2-026F-4832-B726-B83EAB1A1DBBQ36355475-EBBEBA2C-8CAF-4971-9678-9281A44018AFQ36538938-9DCFAB06-E062-4740-BC4F-D66E28E453BAQ37194666-0C2772D2-5BD2-4367-97E5-F0DFB2DCBEB8Q37761853-94DF5C3D-D144-4F0B-B531-4F51AF37D24DQ38036063-3D8813F9-7537-4D84-896F-AACBD26E4316Q38180377-28B5ECEF-633D-4F97-A77A-BD75342A737EQ38611038-73C008B4-03E3-4A85-9AD9-B440546F7EC2Q38672968-A65AAD9C-8545-4DA7-A902-98940FE75FEEQ39302977-9D3AA432-D145-47EA-89F9-1251316EEDDAQ40143544-80C74390-6EB1-4713-A290-93D36C02AC33Q40195987-46EAAFB0-E95F-453D-A000-8FAFB55167ECQ40817024-7862543D-723A-4E2B-9FA8-D1DE4A5BD72BQ41070585-991896CB-62ED-4D59-824A-A0F63865B9BBQ41453384-0D40FF86-CE2B-4147-B0EA-CCE9CCD3C1F2Q41511107-19599C23-E212-4D06-8717-966E9AD3739CQ41613009-2A83B3C7-6354-4E02-BD44-3353E1701F39Q41759752-844015FD-5BD6-4A48-A6DD-B89FCDBCEBB6Q41990756-4980DE88-D3B1-48C8-BE70-2D8635DDD6DCQ42038637-8F86541D-33F0-4B9E-BF58-108B20ED0EDAQ42211446-D8AACA73-2905-4F1F-96E4-773EAB2FF66CQ42222753-1B3ED28E-4E23-4F5E-9EEC-E809B4485142Q42234700-596F79BF-4204-44F1-85BF-74201EF1E234Q42237059-AF2ED044-E532-434B-81C3-E9A8AB29F8C9Q42237404-F3DD25BA-060E-4E2F-9042-A8D568D2F7F8
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paolo Rossi
@ast
Paolo Rossi
@da
Paolo Rossi
@de
Paolo Rossi
@en
Paolo Rossi
@es
Paolo Rossi
@fo
Paolo Rossi
@fr
Paolo Rossi
@is
Paolo Rossi
@kl
Paolo Rossi
@nb
type
label
Paolo Rossi
@ast
Paolo Rossi
@da
Paolo Rossi
@de
Paolo Rossi
@en
Paolo Rossi
@es
Paolo Rossi
@fo
Paolo Rossi
@fr
Paolo Rossi
@is
Paolo Rossi
@kl
Paolo Rossi
@nb
prefLabel
Paolo Rossi
@ast
Paolo Rossi
@da
Paolo Rossi
@de
Paolo Rossi
@en
Paolo Rossi
@es
Paolo Rossi
@fo
Paolo Rossi
@fr
Paolo Rossi
@is
Paolo Rossi
@kl
Paolo Rossi
@nb
P106
P1153
35314392700
P31
P496
0000-0003-2620-7918